Harmony Biosciences Holdings (HRMY) EBT (2019 - 2026)

Harmony Biosciences Holdings has disclosed EBT across 8 years of filings, most recently posting $39.7 million for Q1 2026.

• EBT for Q1 2026 came in at $39.7 million, down 30.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $197.6 million (changed 0.19% YoY), and the FY2025 annual result was $215.1 million, up 12.13% from the prior year.
• EBT came in at $39.7 million for Q1 2026 at Harmony Biosciences Holdings, down from $40.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $67.5 million in Q3 2025 to a low of $8.0 million in Q3 2022.
• The 5-year median for EBT is $44.1 million (2023), against an average of $42.6 million.
• Across the five-year window, EBT surged 550.58% in 2023 and sank 50.8% in 2024, its largest moves.
• Harmony Biosciences Holdings' EBT stood at $44.1 million in 2022, then declined by 10.01% to $39.7 million in 2023, then surged by 41.49% to $56.2 million in 2024, then declined by 27.42% to $40.8 million in 2025, then declined by 2.63% to $39.7 million in 2026.
• The last three EBT figures came in at $39.7 million (Q1 2026), $40.8 million (Q4 2025), and $67.5 million (Q3 2025), per Business Quant data.